Besides, we confirmed that the SMYD3 inhibitor BCI-121 significantly diminished Thr 308 phosphorylation levels of AKT1; this inhibitor effectively repressed the growth of cancer cells overexpressing SMYD3 [19], further supporting the potential of SMYD3 as a target of anti-cancer drug development. Here, SMYD3 is linked to cancer.